Yousha Neman-Ebrahim
Known title: Chief Clinical OfficerCIK: 0002071642
Yousha Neman-Ebrahim's purchase track record
Yousha Neman-Ebrahim has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/23/2026 | NTHI | $2K | -24.2% | pending | — |
| 11/20/2025 | NTHI | $7K | +45.0% | -9.6% | +13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NTHI | ▲ Buy | Open Market | 500 | $2K | 4/23/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 1,100 | $7K | 11/20/2025 | View on chart |
| NTHI | ▲ Buy | Grant | 133,000 | — | 6/5/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage
NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage. NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.